Brian Mann

As the nation's addiction crisis deepened, Tamara Beetham, who studies health policy at Yale University, set out to answer a simple question: What happens when people try to get help?

Her first step was to create a kind of undercover identity — a 26-year-old, using heroin daily. Using this fictional persona, her research team called more than 600 residential treatment centers all over the country.

"We'd kind of call and say, I'm looking to, you know, start treatment and kind of go from there," Beetham said.

Officials in New York say they're working to overcome resistance to the coronavirus vaccine in the Black and Latino communities, while also trying to make doses more readily available.

New state data released Friday showed many Black New Yorkers aren't taking the vaccine even when it's offered free of charge.

Only 39% of Black New Yorkers said they'd take the vaccine as soon as it was available to them, according to the state data. Hispanic New Yorkers were somewhat less hesitant, at 54%.

McKinsey & Company has reached a $573 million settlement with nearly 50 state governments as well as the District of Columbia and territories, over its role helping to market and boost sales of high-risk opioids including OxyContin.

Most of the funds will be devoted to paying for treatment and rehabilitation programs in communities devastated by the addiction crisis. As part of the settlement, McKinsey admits to no wrongdoing.

This deal heads off civil lawsuits threatened by state attorneys general.

In the weeks after winning the November election, Joe Biden began naming officials to tackle the vortex of crises his administration would face on day one.

The Trump administration introduced new addiction treatment guidelines Thursday that give physicians more flexibility to prescribe a drug to patients struggling with opioid addiction.

When Ashwani Sheoran showed up for early morning shifts at pharmacies in rural Michigan wearing his white Walmart smock, he often found customers waiting, desperate for bottles of pain pills.

"I see my patients, 15 to 20, already lined up to get prescriptions filled for morphine sulfate, oxycodone and other straight narcotics," he said.

This was in 2012 when the prescription opioid epidemic was exploding, killing tens of thousands of Americans every year.

Updated at 1:22 p.m. ET

Members of the Sackler family and Purdue Pharma's CEO say they did nothing wrong during the years their company illegally marketed Oxycontin and other opioids.

"There's nothing I can find that I would have done differently," said Dr. Kathe Sackler who served on Purdue's board for nearly 20 years.

One of the world's most influential corporate consulting firms, McKinsey & Company, says it regrets efforts to boost sales of OxyContin and other highly addictive opioids.

The rare apology follows revelations in documents made public last month for the first time that showed McKinsey working closely with Purdue Pharma and members of the Sackler family who sat on Purdue's board.